Rivaroxaban: A Review for Secondary CV Prevention in CAD and PAD | SpringerLink
Rivaroxaban Plus Aspirin Versus Aspirin in Relation to Vascular Risk in the COMPASS Trial | Journal of the American College of Cardiology
Eikelboom Net Clinical Benefit Video | XARELTO® (rivaroxaban)
Rivaroxaban Plus Aspirin in Patients With Vascular Disease and Renal Dysfunction: From the COMPASS Trial | Journal of the American College of Cardiology
COMPASS Trial Insights into Aspirin and Rivaroxaban Combined Therapy, October 13 2017 - YouTube
Peripheral Artery Disease, the Factor Xa Inhibitor Rivaroxaban, and the Role of the Podiatrist
MEDVASC - VOYAGER : le rivaroxaban 2,5 mg X 2, c'est oui
عبدالله خربوش on X: "COMPASS trial: Rivaroxaban with or without aspirin in stable CVD. The NEJM. 2017. epub 2017-08-27:1-12. Further evidence of increased major bleeding with this approach will necessitate careful consideration
COMPASS: Clinical Trial - Post Revascularization & Chronic PAD | XARELTO® ( rivaroxaban) HCP
Rivaroxaban con o sin Aspirina en enfermedad cardiovascular estable – Estudio COMPASS
The COMPASS Trial | Circulation
COMPASS study of Janssen's rivaroxaban to end early for efficacy - 526 Fulham Rd, Fulham, London SW6, UK
Rivaroxaban Plus Aspirin in Obese and Overweight Patients With Vascular Disease in the COMPASS Trial - ScienceDirect
Efficacy Profile - Chronic CAD/PAD | XARELTO® (rivaroxaban) HCP
Rivaroxaban and Aspirin in Peripheral Vascular Disease: a Review of Implementation Strategies and Management of Common Clinical Scenarios | Current Cardiology Reports
COMPASS Trial Shows Rivaroxaban and Aspirin Lowers Major Adverse Limb Events in Peripheral Artery Disease | DAIC
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial - The Lancet
Épisode 10 : Étude COMPASS - BaladoCritique : Club de lecture médical - Université de Sherbrooke
The COMPASS Trial | Circulation
C. Michael Gibson MD on X: "Here is the design of the COMPASS trial of > 27,000 patients that was shut down due to overwhelming superiority of rivaroxaban https://t.co/abziReBQNk" / X
COMPASS : Rivaroxaban + aspirine chez le vasculaire
Xarelto® (Rivaroxaban) - COMPASS-studien - Xarelto i kombination med ASA vid kranskärlsjukdom
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease | NEJM
COMPASS - Research Studies - PHRI - Population Health Research Institute of Canada
